Share

July 2020; 7 (4) ArticleOpen Access

COVID-19 and MS disease-modifying therapies

Joseph R. Berger, Rachel Brandstadter, Amit Bar-Or
First published May 15, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000761
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
3960

Share

Article Information

vol. 7 no. 4 e761
DOI: 
https://doi.org/10.1212/NXI.0000000000000761
PubMed: 
32414755
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received April 16, 2020
  • Accepted in final form April 26, 2020
  • First Published May 15, 2020.
Copyright & Usage: 
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Joseph R. Berger, MD,
    2. Rachel Brandstadter, MD and
    3. Amit Bar-Or, MD
  1. Joseph R. Berger, MD,
    2. Scientific Advisory Boards:

    1. Dr. Berger serves as a consultant and/or on the PML adjudication committees of Novartis and Takeda/Millennium. He also serves on the Scientific Advisory Board ExcisionBio and Inhibikase. He is chair of the Data Safety Monitoring Board for MAPI.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Dr. Berger has received honoraria from Prime Education, AcademicCME, Arcus Medica, Eisenhower Medical Center, River West Meetings, and the MS Foundation for lectures.

    Editorial Boards:

    1. Dr. Berger serves as an editorial board member of the Journal of Neurovirology, Neurology Reviews and MS and Related Disorders

    Patents:

    1. NONE

    Publishing Royalties:

    1. Portegies P, Berger JR (Editors): HIV/AIDS and the Nervous System. In Vinken PJ, Bruyn G (Editors): Handbook of Clinical Neurology, Volume 85; Elsevier, Amsterdam, 2007.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr. Berger serves as a consultant to Biogen, Celgene, Dr. Reddy, EMD Serono, Genzyme/Sanofi, Merck, Novartis, Roche/Genentech, Morphic, Encycle, Novartis, and Millennium/Takeda.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1) Biogen 2) Genentech

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Rachel Brandstadter, MD and
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Amit Bar-Or, MD
    4. Scientific Advisory Boards:

    1. Receptos-Celgene, Advisor, Scientific Board, 2011 - Sanofi/Genzyme, Advisor, Scientific board, 2017 - Roche/Genentech, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- GSK, Advisor 2012 - 2014 Atara Therapeutics, Advisor, Scientific Board, 2017 - Guthy Jackson Greater Good Foundation, Scientific Advisor, 2008- Immune Tolerance Network - Steering Committee, 2016 -

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Receptos-Celgene, Advisor, Scientific Board, 2011 - Roche/Genentech, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- Sanofi-Genzyme 2015- GSK, Advisor 2012 - 2014

    Editorial Boards:

    1. (1) Neurology, Editorial Board Member, 2008-2015 (2) Clinical and Experimental Neuroimmunology, Editorial Board Member, 2010 -

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Receptos-Celgene, Advisor, Scientific Board, 2011 - Roche/Genentech, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- Sanofi-genzyme - Advisor, 2015 - GSK, Advisor 2012 - 2014 Atara Therapeutics, Advisor, Scientific Board, 2017 -

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis (2) Genzyme-Sanofi (3) Biogen (4) Merck/EMDSerono (5) Roche/Genentech

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Division of Multiple Sclerosis, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  1. Correspondence
    Dr. Berger joseph.berger{at}pennmedicine.upenn.edu
View Full Text

Article usage

Article usage: May 2020 to July 2022

AbstractFullPdfSource
May 2020932049837Highwire
Jun 2020511429491Highwire
Jul 20203062248456Highwire
Aug 2020631992261Highwire
Sep 2020441801226Highwire
Oct 2020431355224Highwire
Nov 2020431300153Highwire
Dec 2020301627101Highwire
Jan 2021491315176Highwire
Feb 202151921109Highwire
Mar 20213066298Highwire
Apr 20214170673Highwire
May 20215688250Highwire
Jun 20213588584Highwire
Jul 20213773249Highwire
Aug 20211999363Highwire
Sep 20212980069Highwire
Oct 20213578865Highwire
Nov 20213463365Highwire
Dec 20212044047Highwire
Jan 20222837540Highwire
Feb 20222416540Highwire
Mar 20224320249Highwire
Apr 20222612136Highwire
May 20222715152Highwire
Jun 20222617729Highwire
Jul 2022616117Highwire

Cited By...

Letters: Rapid online correspondence

Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Advertisement